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Lipid-based liquid crystals as drug delivery vehicles for antimicrobial peptides 
 
 
LUKAS BOGE 
 
Department of Chemistry and Chemical engineering 
CHALMERS UNIVERSITY OF TECHNOLOGY 
Abstract 
The development of antimicrobial resistance is a great challenge within the health sector 
around the world. The demand for new efficient treatments is alarming in order to treat 
various bacterial infections in the near future. Antimicrobial peptides (AMPs) are a group of 
novel antibiotics that have gain more and more attraction the past decade. However, AMPs 
suffers from relatively low stability due to proteolytic and chemical degradation. As a 
consequence, carrier systems protecting the AMPs are highly needed for achieving efficient 
treatments. In this thesis, lyotropic liquid crystalline (LC) structures consisting of cubic 
glycerol monooleate/water and hexagonal glycerol monooleate/oleic acid/water have been 
examined as carriers for three AMPs (AP114, DPK-060 and LL-37). Both bulk gels and 
discrete dispersed structures, i.e. cubosomes and hexosomes have been studied. Moreover, 
two different peptide loading approaches for the cubosomes were tested and compared; pre- 
and post-loading. Characterization of the LC structures was performed using small-angle x-
ray scattering (SAXS), dynamic light scattering, ζ-potential, and cryogenic transmission 
electron microscopy (Cryo-TEM) and peptide loading efficacy by liquid chromatography. 
The antimicrobial effect of the AMP loaded LC nanoparticles (LCNPs) was studied in vitro 
using minimum inhibitory concentration (MIC) and time-kill assays. Proteolytic protection 
was investigated by incubating the formulations with two elastases and the antimicrobial 
effect after proteolysis was studied using radial diffusion assay (RDA).  
Results showed that the most hydrophobic peptide (AP114) was prone to induce an increase 
in negative curvature of the bulk cubic LC gel, hence pushing the system towards a hexagonal 
structure. The most polar peptide (DPK-060) induced a decrease in negative curvature while 
LL-37 did not change the LC phase at all. The hexagonal LC phase was not affected by any of 
the AMPs. The cubic pre- and post-loaded LCNPs displayed promising antimicrobial activity, 
and sometimes could a synergetic effect be observed, resulting in a slightly better activity 
than the unformulated AMP. The hexagonal LCNPs were found to be very efficient in 
encapsulating the AMPs, but did not display any antimicrobial effect, indicating insufficient 
delivery of peptide to the bacteria. Moreover, cubosomes post-loaded with LL-37 was found 
to protect the peptide from proteolytic degradation, resulting in a significant better 
bactericidal effect after proteolysis. 
 
Keywords: Liquid crystals, liquid crystalline nanoparticles, cubosome, hexosome, 
antimicrobial peptide, AMP, glycerol monooleate, proteolysis 
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1. Introduction 
 
The development of antimicrobial resistance of pathogenic bacteria is a great challenge within 
the health sector, all around the world. Estimations point out that up to 70% of the hospital 
acquired infections in the United States are caused by bacteria resistant to one or more 
antibiotics [1]. Since the discovery and deployment of penicillin in the 1940’s, bacteria have 
developed resistance to all new types of antibiotics, in some cases just after a few years of 
use. In the past 40 years no new classes of antibiotics used clinically has been discovered, 
except two types of narrow spectrum drugs. Moreover, antimicrobial resistance is listed as 
one of the biggest threats to global health and development by the World Health Organization 
(WHO) and high rates of resistance development is observed over the planet. In the latest 
WHO report “Antimicrobial resistance: global report on surveillance” (2014) it was found 
that >50% of the bacteria commonly causing infections in hospitals and in the community 
(e.g. Escherichia coli and Staphylococcus aureus) had a reduced susceptibility to commonly 
used antibiotic treatments [2].  
The demand for new efficient treatments is apparently alarming. It is doubtless a must in 
order to be able to treat various bacterial infections, large or small, in the future. A group of 
novel antimicrobial agents that has gained a lot of attraction since the early 1980’s are 
antimicrobial peptides (AMPs) [3]. These peptides generally display a very quick, and usually 
broad spectrum, bacterial killing among being said to be less prone to develop high level 
resistance [3, 4].  AMP’s common susceptibility to chemical and proteolytic degradation has 
limit AMPs in clinical use, but may be overcome by clever formulation strategies [5]. This 
thesis describes the use of liquid crystalline phases, and dispersions of those into 
nanoparticles, for delivery of AMPs. 
1.1. Aim of this thesis 
The aim of this thesis was to evaluate how three AMPs influenced the structure of cubic and 
hexagonal LC gel, and to study the suitability of LCNPs as drug delivery vehicles. Two 
different AMP loading approaches were investigated, presented in Figure 1, and compared, 
namely:  
a) Pre-loading , where AMPs are incorporated into the LC gel prior dispersion 
into LCNPs 
b) Post-loading, where the AMPs are let to associate onto pre-formed LCNPs  
The antimicrobial effect of the AMP loaded LCNPs was studied in vitro, in order to reveal if 
the formulations could preserve, or even enhance the antimicrobial activity. It was also 
investigated if the particles could protect the AMPs from enzymatic degradation, and if any 
antimicrobial effect still was present after proteolysis.  
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Figure 1. Schematical representation of the two AMP loading strategies investigated in this thesis; A) dispersion 
of LC gels pre-loaded with AMP, and B) where AMPs are let to associate onto LCNPs after preparation of the 
particles. 
 
1.2. Background 
1.2.1. Antimicrobial peptides 
AMPs are present in all organisms as part of the innate defense system, thus making up the 
body’s first response towards pathogenic bacteria. These peptides are promising therapeutics 
to treat various infectious diseases, due to their fast and non-specific mechanism of action [3, 
4]. Bacteria are often said to be less prone to develop resistance against AMPs compared to 
traditionally used antibiotics. However, it has been shown that bacteria may develop 
resistance against AMPs and this issue needs to be carefully studied before translation into 
clinics [6].  AMPs are generally amphipathic molecules consisting of <45 amino acids, of 
which a substantial fraction are normally hydrophobic residues, and carries a net positive 
charge [7]. The positive net charge of the AMPs is an important property, driving the 
adsorption towards the negatively charged phospholipid head groups of the bacterial outer 
membrane, making strong interactions and penetration possible. There are several models as 
illustrated in Figure 2, describing the mode of action of AMPs, involving the barrel-stave, 
carpet and toroidal pore models [3]. All these models have in common that the AMP results in 
the formation of pores/defects within the bacterial membrane, leading to cell wall rupture and 
finally death. 
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Figure 2. Models commonly used for describing the mechanism of killing bacteria by AMPs. AMPs are usually 
unstructured in aqueous solutions and change conformation upon adsorption and insertion in a bacterial 
membrane. If the AMP targets internal receptors of the cell, translocation through the membrane into the 
cytoplasm can also occur (not shown in illustration). 
1.2.2. Antimicrobial peptides in this thesis 
Three AMPs with differences in terms of size, charge, hydrophobicity, secondary structure 
and activity were chosen to study in this thesis. Peptide AP114 (also known as NZ2114) is a 
plectasin derivative derived from the fungus Pseudoplectania nigrella (“ebony cup” or “svart 
vårskål”), and kills bacteria by translocation through the bacterial membrane and inhibiting 
the membrane biosynthesis, through targeting of the cellular precursor Lipid II [8, 9]. Hence, 
the mechanism of action for AP114 differs from the more traditional killing models. The 
broad-spectrum antimicrobial peptide DPK-060 (also known as GKH17-WWW) is derived 
from the endogenous human protein kininogen [10]. The peptide is intended for topical 
administration to treat a variety of infected skin conditions [10]. Its effect has been confirmed 
by clinical phase II studies as treatment for infections in atopic dermatitis and acute external 
otitis [5]. LL-37 is the only known human peptide in the cathelicidin family, also showing a 
broad spectrum bacterial killing [11]. Its secondary structure normally changes from random 
coil in aqueous environment to α-helix upon membrane interaction. The peptide is sensitive to 
proteolytic degradation by enzymes, which has so far limited its therapeutic use [12]. Table 1 
summarizes the properties of the AMPs. 
Table 1. Properties of the antimicrobial peptides used in the thesis. 
Peptide Sequence MW % hydrophobic 
AA  
Net charge 
 (pH 5.5) 
Secondary 
structure 
Antibacterial 
activity 
AP114 GFGCNGPWNEDDLRCHNHCKSI-KGYKGGYCAKGGFVCKCY 4411 40 +4.6 
β-sheet, α-helix Gram-positive 
DPK-060 GKHKNKGKKNGKHNGWKWWW 2503 20 +8.5 Random coil Broad spectrum 
LL-37 LLGDFFRKSKEKIGKEFKRIVQR-IKDFLRNLVPRTES 4491 35 +6.3 
α-helix, random 
coil Broad spectrum 
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1.2.3. Lipid-based liquid crystals in drug delivery 
LC phases are formed spontaneously upon hydration of certain amphiphilic molecules, e.g. 
polar lipids. The driving force for this self-assembly process of polar lipids into LC phases is 
the phenomenon often referred to as the “hydrophobic effect” [13, 14]. There are three main 
types of LC phases: the lamellar phase, the hexagonal phase and cubic phases with very 
complex 3-dimensional architectures. The LC phases are schematically presented in Figure 3 
below.  
 
Figure 3. Schematically representation of the three major groups of liquid crystals; lamellar, hexagonal and 
cubic phase. 
LC phases of polar lipids are of great interest in drug delivery because of their capability to 
encapsulate a broad range of drugs, ranging from hydrophobic to hydrophilic, as well as 
amphiphilic ones. Moreover, these systems are also biocompatible and degradable in the body 
[13]. One of the most extensively studied polar lipid in drug delivery is glycerol monooleate 
(GMO). GMO is known to have a very rich phase behavior with water, making room for 
many interesting drug delivery opportunities [15]. The water-GMO phase diagram is 
presented in Figure 4. Depending on the nature of the introduced guest molecules in such LC 
systems, e.g. the polarity and molecular structure, the molecules will be located either in the 
water or lipophilic domains of the system [16]. It has been shown that addition of lipophilic 
compounds to the GMO/water LC cubic system induce transition to a reverse hexagonal 
phase (increased negative curvature), while molecules having a pronounced amphiphilic 
character can induce transition to a lamellar LC phase (decreased negative curvature) [13, 17, 
18]. AMPs comprising differences in amphiphilicity could be prone to induce similar phase 
transitions, when incorporated in such systems. Phase transitions have previously been shown 
for a variety of protein loaded LC systems [19-25]. In this work, the effect of incorporating 
three AMPs into a cubic and a hexagonal LC gel was studied. 
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Figure 4. Water-GMO phase diagram displaying a rich variety of LC phases. The coexistence of LC phase and 
water enables fragmentation of bulk gel into LCNPs. Reprinted from  [15], with permission from Elsevier. 
1.2.4. Liquid crystalline nanoparticles in drug delivery 
One feature making LC systems of polar lipids even more interesting for drug delivery is the 
fact that some systems can coexist with excess of water. This enables fragmentation of bulk 
gels into LC nanoparticles (LCNPs), using a suitable stabilizer [26, 27]. A dispersion of cubic 
phase is commonly referred to as “cubosomes” while a dispersion of hexagonal phase is 
referred to as “hexosomes”. By doing this, one can overcome the usually sticky and highly 
viscous nature of the LC gels, which can be advantageous from a drug delivery perspective. 
Polar peptides and proteins can be incorporated in LCNPs and possibly be less subjected to 
chemical and proteolytic degradation [14, 28-30]. LCNPs can be prepared by sonication [27] 
or high pressure homogenizing using a microfluidizer [31] of bulk gel. Another preparation 
method involves dilution of an isotropic mixture of lipid and ethanol, commonly referred to as 
“the hydrotrope method” [32].  These preparation protocols have the drawback that they also 
produce a large fraction of vesicles among with the desired LCNPs (usually cubosomes or 
hexosomes) as can be revealed by cryo-TEM imaging. A way to reduce the number of 
vesicles is to heat treat the sonicated or microfluidized dispersions in an autoclave [33]. This 
treatment has several advantages, namely: 1) drastically reducing the number of small 
vesicles, 2) narrowing down the overall particle size distribution and 3) the final particle 
dispersion is sterile and suitable for pharmaceutical use.  
Drug loaded LCNPs are typically obtained by adding the drugs either to the molten lipid 
phase (lipophilic drugs) or to the water phase (hydrophilic drugs) prior dispersion into 
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nanoparticles. However, peptide and protein drugs are often sensitive to high temperature, 
which may be induced by high shearing rates during fragmentation or during sterilization of 
the formulations. Hence, the number of preparation techniques for producing drug loaded 
LCNPs with high degree of uniformity is limited. One formulation strategy to form uniform 
drug containing LCNPs is to let a water soluble drug adsorb onto the surface of pre-formed 
heat treated LCNPs using electrostatic and/or hydrophobic interactions. This is possible since 
LCNPs usually have a slightly negatively zeta-potential, and would apparently attract 
antimicrobial peptides with a positive net charge. LCNPs have previously been investigated 
as carrier system for several peptides and proteins; insulin (pre-loading) [34], ovalbumin (pre-
loading) [35-37], somatostatin (post-loading) [38] and cyclosporine A (pre-loading) [39, 40] 
only to mention a few. These studies report encouraging results in terms of observed blood 
glucose values (insulin, in vivo, rat), sustained release properties (ovalbumin, in vivo, rat), 
increased half-life time (somatostatin, in vivo, rat) and increased peptide skin penetration 
(cyclosporine A, in vivo, mice).    
Taking the previously reported sustained release properties and protection against proteolytic 
degradation into account, makes LCNPs interesting drug delivery vehicles for a variety of 
peptides, such as AMPs. 
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2. Experimental 
2.1. Materials 
Glycerol monooleate (GMO) RYLO MG 19 Pharma was received from Danisco A/S 
(Grindsted, Denmark). The composition of the sample according to the manufacturer was 
min. 95% monoglyceride. The fatty acid content was minimum 88% oleoyl (C18:1). Super 
refined oleic acid NF-LQ-(MH) was purchased from Croda Inc. (Snaith, UK). The triblock 
copolymeric stabilizer Kolliphor® P407 poly(ethylene oxide)(PEO)-poly(propylene 
oxide)(PPO)-poly(ethylene oxide)(PEO) was obtained from BASF (Lundwigshafen, 
Germany) and had an approximate formula of PEO101PPO56PEO101 and an average molecular 
weight of 12600 g/mol. Antimicrobial peptide AP114 purity 99.1% was provided by Adenium 
Biotech ApS (Copenhagen, Denmark), DPK-060 (acetate salt) purity 98.5% (72.7% taking 
the acetate counter ion into account) was synthesized by Bachem AG (Bubendorf, 
Swizerland) and provided by Pergamum AB (Stockholm, Sweden) and LL-37 purity 94.7% 
was synthesized and provided by PolyPeptide Laboratories (Limhamn, Sweden). 
2.2. Sample preparation 
2.2.1. Liquid crystalline bulk gels 
LC gels were prepared by mixing melted GMO or GMO/OA (80:20 w/w) at 40 °C with a 
water solution containing AMP, resulting in LC gels containing 0.5, 1.0 and 1.5 w% peptide 
(if nothing else stated). Samples were homogenized with spatula, centrifuged at 3000 rpm for 
1 hour and allowed to equilibrate at room temperature for at least 1 week prior further use. 
The lipid to water ratio for the LC gels prepared without AMP were chosen to obtain the 
cubic (70:30 w/w) or hexagonal phase (80:20 w/w), so the peptide’s impact of the curvature 
could be investigated. 
2.2.2. Liquid crystalline nanoparticles 
Pre-loaded LCNPs 
Dispersions of the LC phases were made by fragmenting 5 w%  (0.5 g) LC gel in 9.5 g 1.0% 
P407, dissolved in 5mM acetic acid buffer pH 5.5, using an Ultra-Turrax high shear mixer 
(IKA T25, Staufen, Germany) operated at 15.000 rpm for 1-2 min. The coarse dispersion was 
ultra-sonicated using a Vibra-Cell VC 750 (Sonics and Materials Inc., Newton, USA) 
equipped  with a 6 mm probe operating at 40% of its maximum power in puls mode (3 s 
pulses followed by 7 break) for a total time of 5 min (cubic GMO dispersions) or 10 min 
(hexagonal GMO/OA dispersions).  
Post-loaded LCNPs 
Particles used for post-loading of AMP were prepared by dispersing a pre-formed cubic LC 
gel (GMO:water 70:30, no peptide added) as described above, followed by a heat treatment 
cycle of the sample, in order to narrow down the particle size distribution and to reduce the 
number of vesicles [33]. The heat treatment was done using a Laboklav 25 autoclave (SHP 
Steriltechnik AG, Schloss Detzel/Satuelle, Germany) at 121°C for 20 min. The final 
cubosome concentration was defined as the total dry content after the sterilization, in mg/mL 
of GMO+ P407, and quantified after removal of water through lyophilization (Epsilon 2-4 
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LSC plus, Martin Christ GmbH, Osterode am Harz, Germany) of the sample. Thereafter, 
samples containing 5 and 10 mg/mL cubosomes with AMP content of 0.10 mg/mL were 
prepared in 5 mM sodium acetate buffer pH 5.5. Two different concentrations of particles 
were chosen in order to investigate how it affected the peptide association. Samples were let 
to equilibrate for 24 hours at 22±1°C prior further analyses. 
2.3. Analytical methods 
2.3.1. Particle size measurements 
The particle size and the particle size distribution of the LCNPs were measured by dynamic 
light scattering using a Ζetasizer Zen3600 instrument (Malvern Instruments Ltd., 
Worcestershire, U.K.) using disposable cuvettes. Refractive indices were set to 1.47 and 1.33, 
for lipids and water respectively, and the temperature during the measurement was 25°C 
during the measurements. The hydrodynamic radius, assuming spherical particles, was 
calculated by the software using Stoke-Einstein´s relation to describe the Brownian motion of 
the particles. Each sample was measured in triplicate. 
2.3.2. Zeta-potential 
The zeta (ζ) -potential of the particles was determined by measuring the electrophoretic 
mobility using a Ζetasizer Zen3600 (Malvern Instruments Ltd., Worcestershire, U.K.) using 
the Smoluchowski model. Samples were diluted in MilliQ water (pre-loaded particles) or in 5 
mM sodium acetate buffer pH 5.5 (post-loaded particles) to a particle concentration of 1-2.5 
mg/mL and analyzed in disposable measuring cells at 25°C. Each sample was run in triplicate. 
2.3.3. Small angle x-ray scattering 
The LC structure of bulk gels and LCNPs was determined using SAXS. Measurements were 
performed at beamline I911-SAXS (MAX IV Laboratory, Lund, Sweden) equipped with a 
fast read-out pixel detector PILATUS 1M (Dectris Ltd., Baden, Switzerland) [41]. Liquid 
crystalline gels were mounted in a multiple sample holder made of steel and fitted between 
kapton sheets, whereas liquid samples were loaded into quartz capillaries (ID 1.0 mm) 
mounted in a steel holder. Samples were subjected to a flux of ͷ ή ͳͲଵ଴ photons/s with a beam 
size of 0.3ൈ0.3 mm2 at a wavelength of 0.91 Å. The exposure time was 100 s for each sample. 
Measurements were carried out in air at 22 and at 37°C for selected samples. Collected 2D 
raw-data images were analyzed using the software Bli911-4 GUI version 4.12  and the LC 
mesophases were identified according to Bragg peak spacing’s [42].  
2.3.4. Quantification of encapsulated antimicrobial peptide 
Liquid chromatography was used to quantify the encapsulated (pre-loaded particles) and 
cubosome-associated AMP (post-loaded particles). LCNPs were removed from the 
surrounding liquid by centrifugation at 10 000g for 30 min through Amicon Ultra-0.5 filter 
devices (Ultracel-100K, Merck Millipore Ltd. Corc, Ireland) with a 100 kDa molecular 
weight cut-off. The concentration of peptide in the filtrate was determined using UPLC or 
HPLC using a calibration curve and a correction factor compensating for adsorption to the 
filter. The amount peptide incorporated or associated to the LCNPs could then be calculated, 
as% of total added peptide. Details about the liquid chromatography instrumentation and 
methods can be found in Paper 1 and Paper 2. 
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2.3.5. Release of antimicrobial peptide  
Release of AMP from the post-loaded cubosomes was monitored through dialysis. 1 mL 
sample was placed in a Float-A-Lyzer® G2 dialysis device with 100 kDa molecular weight 
cut-off (Spectrum Laboratories Inc., Rancho Dominques, USA). Samples were let to dialyze 
in 12 mL 5 mM sodium acetate buffer pH 5.5, with or without 150 mM sodium chloride, at 
22±1°C. A 200 μL sample was withdrawn after 0, 1, 2, 4, 6 and 24 h. The AMP release was 
quantified using a fluorescamine assay [43]. 180 μL of the samples was placed in a black 96-
well plate and  20 μL 5 mg/mL fluorescamine (≥98%, Sigma Life Science, Saint Louis, USA) 
dissolved in acetone (99.9%, Sigma-Aldrich) was added to each well just prior fluorescent 
intensity measurement (excitation 360 nm and emission 465 nm) using a CLARIOstar® plate 
reader (GMB biotech, Ortenberg, Germany). Peptide quantification was performed using a 
standard curve.  
2.3.6. Cryogenic transmission electron microscopy 
Cryo-TEM specimens were prepared in a controlled environment vitrification system kept at 
25°C with humidity, close to saturation, to prevent evaporation from the sample during 
preparation. A droplet of the LCNP dispersion was placed onto a carbon-coated holey 
polymer film supported by a copper grid, gently blotted with a filter paper to form a thin 
liquid film (10-500 nm), and immediately plunged into liquid ethane at -180°C. The sample 
grid was then kept at liquid nitrogen temperature and transferred into a Zeiss LIBRA-120 
transmission electron microscope (Carl Zeiss, Oberkochen, Germany) operated at 80kV in 
zero-loss bright-field mode. Digital images were recorded under low dose conditions with a 
TRS slow scan CCD camera system (TRS GmbH, Germany) and iTEM software (Olympus 
Soft Imaging Solutions GmbH, Germany). An underfocus of 1-3 μm was used in order to 
enhance contrast. 
2.3.7. Circular dichroism 
Circular dichroism (CD) spectra were measured by a Jasco J-810 Spectropolarimeter (Jasco, 
Easton, USA). The measurements were performed at 37 °C in a 10 mm quartz cuvette under 
stirring. The samples (100 μg/mL AMP, 10 mg/mL cubosomes) were diluted 5 times with 
buffer prior analysis in order to get a good signal from the instrument. The effect on peptide 
secondary structure was monitored in the range 200–260 nm.  
2.4. In vitro studies 
2.4.1. Microorganisms 
The bacteria used to characterize the antimicrobial activity of the AMP loaded LCNPs were 
Staphylococcus aureus (SA), reference strain ATCC 25923 and 29213, methicillin-resistant 
Staphylococcus aureus (MRSA) clinical strain No. 0702E0196, Pseudomonas aeruginosa 
(PA), reference strain ATCC 27853, ATCC PA01 and clinical strain No. 0704C0134, 
Escherichia coli (EC), reference strain ATCC 25922, and ESBL E. coli, clinical strain 
9007550201, and Acinetobacter baumannii, AYE reference strain ATCC BAA-1710. 
2.4.2. Minimum inhibitory concentration 
The antimicrobial activity of pure peptides and peptide loaded LCNPs was first screened 
using minimum inhibitory concentration (MIC). Serial two-fold dilutions of the tested AMP 
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loaded LCNP samples in brain heart infusion broth (BHI) (BioMérieux, France) for AP114 
containing samples or 1% BHI in water for DPK-060 and LL-37 containing samples were 
prepared in order to obtain the desired concentration range. The density of the microorganism 
suspension was adjusted to 1.1 McFarland standard corresponding to approximately 3.3·108 
colony forming units (CFU)/mL (for SA) or to 0.5 McFarland, approximately 1.5·108 
CFU/mL (PA, EC, A. baumannii). The former suspensions were further diluted 100 times 
(3.3·106 CFU/mL), and the latter were diluted 10 times (1.5·107 CFU/mL) with BHI or 1% 
BHI in water. An aliquot of 100 μL of the bacterial suspension was added into each well of a 
sterile 96 well plate containing 100 μL of the tested sample. Positive controls containing only 
the medium and the bacterial suspension (growth control) and negative control wells, 
containing the medium and the tested sample without the bacterial suspension (sterility 
control), were also prepared. The plates were incubated at 37°C for 24 hours. The MIC was 
defined as the lowest concentration of the sample that completely inhibited the growth of the 
bacteria as detected by the unaided eye. 
2.4.3. Time-kill assay 
To evaluate the bactericidal activity of the samples, time-kill assays were performed. An 
amount of 20 μL of the inoculum (prepared in BHI or 1% BHI in water) was added to a poly-
propylene tube containing 1.98 mL of the tested sample in BHI or 1% BHI. BHI or 1% BHI 
containing the bacterial suspension without the tested sample was used as positive control. 
The samples containing the tested LCNPs, as well as the controls were incubated at 37°C. At 
each sampling time (0, 3, 6 and 24 hours) an amount of 100 μL was withdrawn from each 
tube. Serial 100-fold dilutions were prepared in distilled water when necessary. A 100 μL 
aliquot of the diluted and/or undiluted sample was placed onto the surface of the agar and 
allowed to be absorbed into the agar. After incubation of the agar plates for 24 hours at 37°C, 
the colonies were counted and the cell density in CFU/mL could be calculated. 
2.4.4. Proteolysis 
The peptides and peptides post-loaded on cubosomes (2 μg peptide) were incubated for 6 
hours at 37°C with 0.2 μg Pseudomonas aeruginosa elastase (PE) (261.0 units/mg, BioCol 
GmbH, Potsdam, Germany), or 0.4 μg human neutrophil elastase (HNE) (20.0 units/mg, 
Calbiochem, La Jolla, USA) in a total volume of 15 μL. The materials were analyzed on 10–
20% precast Tris-Tricine sodium dodecyl sulfate polyacrylamide (SDS-PAGE) gels 
(Invitrogen) using electrophoresis and analyzed after staining with coomassie brilliant blue, in 
order to visualize peptide degradation.  
2.4.5. Radial diffusion assay 
Bacteria were grown to mid-logarithmic phase in 10 mL Todd Hewitt (TH) medium and 
washed once with 10 mM Tris buffer pH 7.4. An amount of 4·106 CFU was added to 5 mL of 
the underlay agarose gel (consisting of 1% (w/v) low-electroendosmosis (Low-EEO) type 
agarose, 0.02% (v/v) Tween 20, and 0.03% trypticase soy broth (TSB) (w/v)). The underlay 
was poured into Ø 85 mm petri dishes. Thereafter, 4 mm diameter wells were punched in the 
underlay gel, and 6 μL of the samples were added to each well and the plates were incubated 
at 37°C for 3 hours. The underlay gel was then covered with 5ml of molten overlay gel (6% 
TSB and 1% Low-EEO agarose in water) and incubated at room temperature overnight.  The 
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antimicrobial activity of samples was visualized as a clear zone around each well. The results 
from these experiments are given as mean diameters (n=4-5) of the clear zones formed for the 
different peptide samples. 
2.4.6. Visualization of cells using scanning electron microscopy 
In order to visualize the cell morphology after incubation with AMP loaded LCNPs, bacterial 
samples were prepared for scanning electron microscopy (SEM). The cells were incubated at 
the same cell concentrations as for the time-kill assays. After 9 hours incubation, cells were 
let to adsorb onto poly-L-lysine coated 1*1 cm glass slides for 1 hour, resulting in a total 
incubation of 10 hours. The bacteria suspension was thereafter gently aspirated and replaced 
by fresh phosphate buffered saline (PBS) pH 7.4 twice. Then, fixative solution (2% 
glutaraldehyde and 2% paraformaldehyde in PBS) was added and left overnight at room 
temperature. Following day, samples were rinsed with PBS and dehydrated using an ethanol 
series and thereafter desiccated using hexamethyldisilizane:ethanol 1:1, 1:0 (45 min in each 
solution, last step done twice)  and let dry overnight in a fume hood. Samples were sputtered 
with platinum and transferred into the microscope. Cells were imaged using a Jeol JSM-
6301F scanning microscope (JEOL Ltd, Japan) operated at 3 kV. 
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3. Results and discussion 
 
In this section results are presented with the intention to make comparisons between the two 
LC delivery systems, the cubic GMO/water and the hexagonal GMO/OA/water, and between 
the two different peptide loading approaches for the LCNPs: pre- and post-loading.  The pre-
loaded LC systems are discussed in Paper 1, while the data from the post-loaded systems are 
presented in Paper 2. 
3.1. Phase behavior of antimicrobial peptide loaded liquid crystalline gels 
The effect of incorporating AMPs into cubic and hexagonal LC gels was studied using SAXS, 
and diffractograms are presented in Figure 5. As can be seen in the diffractograms for the 
cubic GMO-based gels, the LC structure was kept for LL-37, changed to another cubic 
symmetry in case of DPK-060 or gradually turned into a hexagonal phase in case of AP114.  
The LC structure of the hexagonal gels was unchanged upon incorporation of any of the 
AMPs at the studied concentrations, and was thus found to be more robust upon peptide 
addition. Lattice parameter calculations are presented in Paper 1. The reference cubic gel (no 
peptide added) belonged to the Ia3d space group, with a lattice parameter of 141.3 Å, in 
agreement with phase diagrams found in literature at 30% water content [15, 44]. When the 
AP114 peptide was added to the system, having the highest percentage of hydrophobic 
residues and lowest net charge among the tested AMPs, the structure gradually turned into the 
hexagonal phase. Hence, AP114 is suggested to interact strongly with the hydrophobic parts 
of the GMO membranes, thus increasing the critical packing parameter (CPP), and in turn 
increasing the negative curvature. Interestingly, the cubic Pn3m phase was detected at lower 
peptide additions, representing a decrease in negative curvature. Transitions from Ia3d to 
Pn3m, and also further to H2, has previously been observed for lipophilic molecules or 
amphiphilic peptides added to GMO based systems [45]. As seen for AP114 at low 
concentrations, DPK-060 changed the structure from cubic Ia3d to cubic Pn3m above 0.5% 
peptide addition. This is probably a result of DPK-060 being the most hydrophilic peptide 
among the examined AMPs and with highest charge. DPK-060 is believed to interact strongly 
with the hydrophilic head groups of GMO, resulting in a decreased CPP and in turn the 
negative curvature. LL-37 did not affect the cubic Ia3d structure, indicating that the peptide is 
mostly located in the water domains of the structure or is penetrating the bilayer interfaces 
without significantly changing the curvature. 
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Figure 5. SAXS diffractograms of cubic GMO:water 70:30 w/w% (A, C, and E) and hexagonal GMO:OA:water 
64:16:20 w/w/w% (B, D and F) LC gels containing AMPs AP114, DPK-060 and LL-37 at different 
concentrations (w%). Representative peak indexing for the cubic Ia3d (A), hexagonal (B) and cubic Pn3m (C) 
symmetries are displayed as the corresponding Miller indices [hkl].  
As mentioned earlier, the hexagonal GMO/OA gels kept their LC structure upon peptide 
addition. However, the lattice parameter for the H2 phase without AMP (48.9 Å) was found to 
increase, represented by the shift of peaks to lower q-values, when any of the AMPs were 
introduced. The observed increase in lattice parameter indicates a swelling of the structure. 
The most hydrophobic peptide, AP114, showed the smallest increase in lattice parameter. The 
reason for this could be that the peptide is mostly located in the lipophilic parts of the 
structure, thus increasing the bulkiness and length of the hydrophobic tails, without changing 
the radius of the water channels. The greatest swelling was observed for DPK-060. Due to its 
high positive net charge and hydrophilicity, DPK-060 is most prone to interact with the polar 
head groups and water domains in the hexagonal structure, thus swelling the cylinders 
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diameter resulting in an increased lattice parameter. Moreover, electrostatic repulsion between 
the positive charges of the AMPs could play a role in the increase of the lattice parameter.  
3.2. Antimicrobial peptide loaded liquid crystalline nanoparticles 
Two different peptide loading approaches were investigated for LCNPs in this work: pre-
loading and post-loading, as previously described in Figure 1. For the pre-loaded LCNPs 
(GMO and GMO/OA-based), the AMPs were added in the LC gel before dispersion into 
nanoparticles using high-shear mixing followed by ultra-sonication. The particles used for 
post-loading (GMO-based cubosomes) were prepared in the same way, but with no AMP 
incorporated in the LC gel from the start, with an additional heat-treatment cycle in an 
autoclave. This treatment is known to narrow down the particle size distribution and to fuse 
smaller vesicles together to cubosomes, or sometimes to larger vesicles. The difference in 
particle size distributions and particle morphology between pre- and post-loaded GMO-based 
particles is presented in Figure 6. The ultra-sonicated particles had a mean particle size of 127 
nm with a polydisperstiy index (PDI) of 0.140, compared to after heat treatment 192 nm with 
PDI of only 0.050. A clear reduction of the number of small vesicles was observed after the 
heat-treatment, as expected. Only GMO-based cubosomes were selected to investigate in 
post-loading approach. This was due to difficulties retaining the hexagonal LC symmetry of 
the particles upon autoclavation of the GMO/OA system, as revealed by SAXS (unpublished 
data). Moreover, the hexagonal LCNPs did not show any antimicrobial activity (section 3.3) 
and was therefore excluded. 
 
Figure 6. Particle size distributions for GMO-based pre-loaded particles (ultra-sonicated) and post-loaded 
particled (ultra-sonication followed by autoclavation) measured by DLS (A). Representative cryo-TEM images 
of pre-loaded particles (B) and post-loaded particles (C), without any AMP, displaying differences in content of 
small unilamellar vesicles. Scale bar equals 100 nm. 
The internal LC structure of the pre- and post-loaded LCNPs were determined using SAXS 
and diffractograms are presented in Figure 7. It was found that the GMO-based pre-loaded 
particles (Figure 7 A, C and E) belonged to the Im3m cubic symmetry, displaying 3 
characteristic Bragg peaks with spacing’s of 21/2: 41/2: 61/2. Interestingly, AP114 containing 
samples displayed hexagonal structure at 1.0 w% peptide loading at 37 °C and at 1.5 w% at 
22 ° C, in agreement with the hexagonal phase found in the LC bulk gels. Samples containing 
DPK-060 and LL-37 did always display cubic Im3m phase. The GMO/OA-based LCNPs 
(Figure 7 B, D and F) displayed presence of hexagonal structure by the 3 peaks with spacing’s 
of 11/2: 31/2: 41/2, in agreement with the results from undispersed gels.  
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Figure 7. SAXS diffractograms of pre-loaded LCNPs (A-F) and post-loaded cubosomes (G). The peptide 
loading in% reflects the initial peptide content in the undispersed LC gel for the pre-loaded particles (A-F). The 
particle concentration for the post-loaded cubosomes was 10 mg/mL and peptide concentration 0.10 mg/mL. 
Representative peak indexing for the cubic Im3m (A and G) and hexagonal (B) symmetries are displayed as the 
corresponding Miller Indices [hkl].  
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The LC structure of the post-loaded cubosomes was also found to belong to the Im3m cubic 
symmetry, and no apparent difference was observed upon peptide addition (Figure 7 G). This 
may indicate that the AMPs are not migrating deeper inside the lipid particles, as we do not 
observe any phase transition e.g. for AP114 in this case, compared to pre-loaded AP114 
(Figure 7 A) displaying presence of hexagonal phase. 
Furthermore, the LCNP dispersions were characterized in terms of particle size, ζ-potential 
and peptide loading efficacy. Results for the pre-loaded cubic GMO and hexagonal GMO/OA 
particles are illustrated in Figure 8. For the cubic LCNPs, the mean particle size was always in 
the range of 100-130 nm with a particle size distribution PDI <0.160. The mean particle size 
for the hexagonal LCNPs was in the range 140-170 nm and showed slightly broader 
distributions of particles (PDI<0.220). In general, pre-loaded GMO-based particles showed 
lower peptide loading efficacies (41-86%), compared to dispersions of GMO/OA hexagonal 
LC gels (>94%).  Different trends in loading efficacy were observed for the peptides loaded in 
the cubic LCNP. No clear trends were observed for the hexagonal GMO/OA system. The ζ-
potential for the pre-loaded references (no AMP added) particles were always negative and 
increased upon peptide incorporation, indicating presence of peptide on the particle surfaces.  
 
Figure 8. Peptide loading efficacy plotted as function of ζ-potential, for pre-loaded cubic (A) and hexagonal (B) 
LCNPs. The diameter of the bubbles is proportional against its mean particle size. The cubic reference equals 
127 nm and the hexagonal 159 nm (unfilled circles). Numbers inside circles represent initial peptide loading 
(w%) in dispersed gels. 
Peptide association onto post-loaded cubosomes was quantified by liquid chromatography 
measurements (Figure 9 A), followed by peptide concentration scans in ζ-potential (Figure 9 
B) and circular dichroism (Figure 9 C). The same trends in peptide encapsulation efficacy 
(AP114<DPK-060<LL-37) seen for the pre-loaded cubic particles, were also observed for the 
post-loaded systems. Peptide located at the cubosome surface was studied at two different 
particle concentrations, 5 and 10 mg/mL, at a fixed peptide concentration of 0.10 mg/mL. 
Samples containing 5 mg/mL particles showed only 7-8% association of the peptides AP114 
and DPK-060. If the concentration of cubosomes was doubled (from 5 to 10 mg/mL AMP 
association to the particles more than doubled, for those two peptides. Interestingly, LL-37 
with properties in between AP114 and DPK-060 in terms of hydrophobicity and net charge, 
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showed a much higher degree of association (>60%) independent of the particle 
concentration. The properties of AP114 having a low positive net charge (+4.6), large fraction 
hydrophobic residues (40%) and high molecular weight (4411 g/mole), did not favor a strong 
association onto the particles. The drastic increase of cubosome-associated AP114 and DPK-
060 when particle concentration was doubled indicates a sensitive equilibrium between 
adsorbed and non-adsorbed peptide, which opens up for trigged release opportunities. One 
could believe that the electrostatic interactions would be the most important factor influencing 
the peptide association to cubosomes. However this hypothesis does not hold in case of DPK-
060 (+8.5), that comprises the highest positive net charge, but still showed lower adsorption 
compared to LL-37 (+6.3).  Hence, the peptide’s hydrophobicity and molecular weight does 
most likely also play a role in the adsorption process. The presence of the positively charged 
AMPs onto cubosomes outer surface was further indicated by the increase in ζ-potential upon 
peptide addition, as displayed in Figure 9 B. Peptide LL-37 showed largest change in ζ-
potential, compared to DPK-060 and AP114 showing smaller changes, in good agreement 
with the trends of liquid chromatography data. The ζ-potential was always slightly negative 
(in absolute values) at lowest peptide concentrations and turned positive at higher 
concentrations. 
CD measurements were performed on post-loaded cubosomes in order to detect any changes 
in peptide secondary structure upon association to the cubosome particles (Figure 9 C).  None 
of the pure AMPs displayed any clear signs of secondary structure and were most likely in a 
random coil conformation. Results for AP114 and LL-37 showed a change in CD spectra with 
two minima approximately at 210 nm and 225 nm, characteristic for a transition into α-helical 
structure in the presence of the cubosomes particles. These findings further indicate that 
peptide association to the cubosome particles takes place. Pure AP114 was expected to 
display presence of β-sheet structure as well, but no clear minima around 215 nm could be 
observed. The transition from a more unordered structure to more helical upon interaction of 
LL-37 with cubosomes, is in good agreement with data reported previously, also displaying 
increase in α-helicity upon membrane adsorption  and vesicle interaction [11, 46].  
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Figure 9. Peptide association efficacy for post-loaded cubosomes (A), peptide association to cubosomes 
monitored as change in ζ-potential (B) and peptide secondary structure measured by CD (C), indicating 
adsorption of peptides on the particle surfaces. Cubosome concentration was 1 mg/mL in the ζ-potential scan and 
2 mg/mL for CD in order to get a good signal from the instruments. The peptide concentration was 20 μg/mL for 
the CD measurements. Data is presented as mean values ± standard deviation (n=3) in diagram A and B. 
Cryo-TEM images of both pre-loaded cubic and hexagonal dispersions as well as post-loaded 
cubosomes, presented in Figure 10, displayed a fraction of dense particles with internal 
structure, in line with the observed diffraction peaks revealed by SAXS. The cubosome 
particles did sometimes carry vesicle structures on the edges. On the other hand, the 
hexosome particles were found to be more round shaped, with a more blurry internal 
repeating structure. A clear reduction in the fraction of small unilamellar vesicles was 
observed for the post-loaded particles (Figure 10 I-L). This was expected, as a result of the 
heat-treatment of the particles prior to the addition of AMPs, in line with cryo-TEM images 
found in the literature [33]. Moreover, the particle size was found to be more homogenous, as 
revealed by the DLS-data presented in Figure 6 A. From Figure 10 A, the repeating distance 
in the cubosome particles was measured to approximately 90-95 Å, also in good agreement 
with the calculated d-spacing from the (110) reflection in the SAXS-data, found to be 135/ξʹ 
=95.5 Å.  
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Figure 10. Cryo-TEM images of pre- and post-loaded LCNPs. Pre-loaded GMO-based (A-D) and GMO/OA-
based (E-H) were loaded with 1 w% AMP prior dispersion resulting in a final concentration of 500 μg/mL.  
Post-loaded GMO-based particles (I-L) contained 100 μg/mL AMP at the higher particle content (10 mg/mL). 
Scale bar equals 100 nm. 
The release of AMP from post-loaded cubosomes was monitored by dialysis in 5 mM sodium 
acetate buffer pH 5.5 with or without physiological salt concentration (150 mM NaCl).  
Results are presented in Figure 11 and show that the release of AP114, DPK-060 and LL-37 
from the cubosomes particles was drastically reduced at higher ionic strength. These data are 
further interpreted in the next section (3.3) about the in vitro effect of the AMP loaded 
particles. Release from pre-loaded cubic and hexagonal LCNPs indicates that only the free 
(non-encapsulated peptide) was transferred over the dialysis membrane. This is due to the fact 
that the total amount of released peptide agrees perfectly with the peptide encapsulation 
efficacy, quantified by UPLC (unpublished data). Hence, one can hypothesize that the 
peptides like to take place in the LC structure, and are not prone to diffuse or leak out from 
the particles. 
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Figure 11. Release of AMP from post-loaded cubosomes including references with only AMP; AP114 (A), 
DPK-060 (B) and LL-37 (C). Each experiment was repeated twice. The release of AMPs from cubosomes 
appeared to be slower at higher ionic strength.  
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3.3. In vitro antibacterial effect  
The first screening of the antimicrobial activity of the peptide-loaded LCNPs was done by 
minimum inhibitory concentration (MIC) tests using 7 different bacterial strains. MIC data is 
presented in Table 2, except for pre-loaded hexagonal GMO/OA particles which did not 
display any antimicrobial activity (MIC >16 μg/mL) for all tested strains. No apparent 
difference concerning the two different particle concentrations (i.e. 5 mg/mL and 10 mg/mL) 
was observed for the post-loaded cubosomes, and data for 10 mg/mL particles is therefore 
only shown.  
Table 2. MIC values for unformulated peptide (UF) and for pre- and post-loaded GMO-based particles. Pre-
loaded particles contained 500 μg/mL AMP and post-loaded 100 μg/mL. The hexagonal (GMO/OA) LCNPs did 
not display any antimicrobial activity at the tested concentrations (MIC >16 μg/mL) for all strains, and were 
therefore excluded in the table below.  
 
In general, AP114 and DPK-060 loaded LCNPs did preserve the antimicrobial effect 
compared to unformulated peptide. LL-37 containing samples showed a slight reduction in its 
usually broad spectrum activity and were only active against gram negative strains. The 
reason for this could be that the peptide needs to be delivered in different ways for different 
bacteria in order to adsorb sufficient and penetrate the membrane. Interestingly, the activity 
for the pre- and post-loaded GMO particles gave very similar MIC values, even though the 
degree of encapsulated or cubosome-associated AMP were different (usually lower for the 
post-loaded). For example pre-loaded particles with DPK-060 with an encapsulation efficacy 
of over 60% performed as well as post-loaded peptide with an association of only 22%. 
Hence, one could have expected a lower activity for the pre-loaded particles if only the free 
peptide was contributing to the bacterial killing, which was not the case. These findings 
indicate that the observed antimicrobial effect of the particles is not only due to the free non-
encapsulated peptide. Moreover, LL-37 loaded particles which showed a very high 
encapsulation efficacy (80% pre-loaded and 60% as post-loaded) had a strong effect against 
gram negative bacteria, such as EC, but no effect on gram positive. Therefore, these findings 
suggest there might be a particle-bacteria interaction, also giving rise to bacterial killing. 
None of the reference particles displayed any antimicrobial effect in the MIC tests. 
The formulations showing promising antimicrobial activity in the MIC tests were further 
characterized using time-kill assays with SA (Figure 12) and EC (Figure 13) bacteria. As 
observed in the MIC tests, formulations containing AP114 showed a similar antimicrobial 
effect against SA at a concentration of 16 μg/mL, compared to unformulated peptide. In case 
  MIC values (μg/mL)  
 AP114 DPK-060 LL-37 
Bacterial strain UF Pre 
(GMO) 
Post 
(GMO) 
UF Pre 
(GMO) 
Post 
(GMO) 
UF Pre 
(GMO) 
Post 
(GMO) 
S. aureus  8 8 8-16 4 2-4 1-2 8-16 >16 >16 
MRSA 4 4 4 4 2-4 2 8-16 >16 >16 
P. aeruginosa  - - - 8 16 8-16 8-16 >16 8-16 
P. aeruginosa clinical strain  - - - 16 8-16 8 8-16 8 8-16 
E. coli  - - - 8 2-4 4 16 16 8-16 
ESBL E. coli clinical strain  - - - 4-8 2-4 2-4 16 >16 ≥16 
A. Baumannii  - - - 4-8 16 16 16 >16 ≥16 
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of post-loaded AP114, 8 μg/mL was found not to be enough for sufficient bacterial killing, as 
seen in Figure 12 B.  
 
Figure 12. Time-kill curves for pre- and post- loaded GMO-based LCNPs containing AP114 (A and B) and 
DPK-060 (C and D) at selected AMP concentrations on Staphylococcus aureus. Each data point is represented 
by mean ± standard deviation (n=3). 
Interestingly, DPK060 post-loaded LCNPs appeared to be slightly more effective against SA 
(Figure 12 D) and EC (Figure 13 B) strains, compared to unformulated DPK060. Post-loaded 
DPK-060 showed a 1-2 dilutions lower MIC on SA, and time-kill experiments confirmed a 
slightly more effective bacterial killing both at 2 and 4 μg/mL. This effect can be considered 
synergistic, as the same trend was observed in both MIC and time-kill experiments. Pre-
loaded DPK-060 and LL-37 displayed a preserved antimicrobial effect on EC (Figure 13 A 
and C). The 1-2 dilutions lower MIC for the DPK-060 sample on EC, could not be confirmed 
by the time-kill assay. The post-loaded LL-37 sample displayed a preserved activity on EC at 
16 μg/mL, but performed surprisingly better than unformulated peptide at only 4 μg/mL. This 
moderate increase in activity could be contributed to the unexpected antimicrobial activity of 
post-loaded reference cubosomes during the first 3 hours on EC (Figure 13 B and D). The 
reason for this effect remains unclear as it was not observed in the MIC test. However, the 
pre-loaded reference particles did never display any antimicrobial effect in the time-kill 
assays.  
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Figure 13. Time-kill curves for pre- and post-loaded LCNPs (GMO-based) with peptides DPK-060 (A and B) 
and LL-37 (C and D) at selected AMP concentrations on Escherichia coli. Each data point is represented by 
mean ± standard deviation (n=3). 
The decrease in antimicrobial activity for the pre-loaded hexagonal GMO/OA LCNPs may be 
explained by that peptides tend to like staying in the hexagonal environment (no phase change 
observed by SAXS) and are thus less prone to leak out. This may explain the high peptide 
loading efficacy (>94%) and will probably result in a very slow release from these particles. 
Our MIC data suggest that the release from the hexagonal particles is very low or non-existing 
during the first 24 hours. Another explanation could be the fact that the ζ-potential of these 
particles always was negative (below -15 mV) giving rise to electrostatic repulsion between 
the particles and negatively charged bacterial membranes, thus hindering a sufficient delivery 
of peptide. 
The release experiments might provide further insight to the in vitro antibacterial effect of the 
formulations. The 100% BHI and 1% BHI medium in water used for in vitro studies contains 
roughly the same ionic strength as the buffer, or with 150 mM NaCl, used for the release 
experiments. The release of AMP from the cubosomes was found be greatest during the first 6 
hours, in line with the killing kinetics shown by the time-kill assays. For a majority of the 
AMP loaded cubosomes, the bacterial killing reached its maximum after 6 hours incubation. 
If the release is as low in the 100% BHI media for AP114 as in the buffer with 150 mM NaCl 
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(only 30% released peptide after 24 hours), one would probably not expect such good 
antimicrobial effect, if not the peptide loaded particle itself will contribute to the bacterial 
killing. The DPK-060 loaded cubosomes displayed a very similar release as for the reference 
peptide in the buffer with no extra salt added. One would thus expect a very similar bacterial 
killing in vitro, which also was the case. However, the slightly synergistic effect observed for 
DPK-060 loaded cubosomes on SA and EC cannot be contributed to differences in release 
profiles. Data suggest it might instead come from a particle-bacteria interaction, giving rise to 
the mild increase in activity. 
In order to visualize the bacterial killing and cell morphology, bacterial samples of SA were 
fixated and dried to enable imaging using SEM. Cells were treated in the same way as for the 
time-kill assay, and viewed after 10 hours incubation. Reference bacterial cells were found in 
large clusters, and displayed a smooth surface morphology, without any apparent damage. 
Moreover, the post-loaded particles on their own were found not to influence the cell 
morphology as expected from the MIC and time-kill experiments. Images of SA cells treated 
with post-loaded cubosomes containing AP114 and DPK-060, including references, are 
displayed in Figure 14. Both pure peptides and peptide-particle formulations displayed a 
drastic reduction in cell density on the glass substrates while viewed in the microscope. 
Bacterial cells subjected to any of the two peptides usually showed a rough surface 
morphology and deformations. Sometimes totally lyzed (Figure 14 C) and “raisin”-like cells 
(Figure 14 E and F) as well as cracks and holes on the surface could be observed, in line with 
previously reported images of AMP treated bacteria [47-49].  
 
Figure 14. SEM images SA treated with AP114 and DPK-060 post-loaded cubosomes after 10 h incubation 
time. Clear cell damage is observed when the cells were subjected to any of the AMPs. Scale bar equals 1 μm. 
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3.4. Proteolytic stability of post-loaded cubosomes 
The proteolytic stability of the pure AMPs and post-loaded on cubosomes was investigated 
using two enzymes; Pseudomonas aeruginosa elastase (PE) and human neutrophil elastase 
(HNE). After incubation with the elastases the samples were separated by size, using gel-
electrophoresis. The data is presented in Figure 15 and showed that AP114 and DPK-060 
(both controls and post-loaded on cubosomes) were not degraded by any of the two enzymes. 
However, pure LL-37 was found to be degraded by both PE and HNE (as seen by the fussy 
bands in Figure 15 B and C), in line with data found in literature [50]. Interestingly, LL-37 
post-loaded cubosomes was shown to protect the peptide against attacks from both PE and 
HNE. It was previously shown that the AMP melittin adsorbed onto lipid-disks particles was 
protected from proteolytic attacks of trypsin [51]. It was hypothesized that the polyethylene 
glycol (PEG) stabilizer located on the rim of the particles provided steric hindrance, blocking 
efficient peptide-enzyme interactions. The block copolymer PEO-PPO-PEO (P407), used as 
stabilizer for the cubosome particles, may protect the LL-37 peptide from enzymatic 
degradation in a similar way. 
 
Figure 15. Proteolysis of post-loaded cubosomes; control samples without any enzyme (A), after 6 hours 
incubation with PE (B) and HNE (C). Results shows that AP114 and DPK-060 was not affected by the enzymes 
(strong bands), while LL-37 was degraded (fuzzy bands). LL-37 was found to be protected against the 
proteolytic attacks if the peptide was loaded onto cubosomes. 
Radial diffusion assay (RDA) was used to investigate the antibacterial effect of post-loaded 
cubosomes as they were (controls) and after proteolysis with PE or HNE. The results are 
shown in Figure 16. As observed in the MIC-tests, it was found that pure AP114 (control) 
showed good bacterial killing against SA. Moreover, it was found that DPK-060 and LL-37 
killed SA, PA and EC, in line with MIC and time-kill assays discussed earlier. Cubosomes 
post-loaded with AP114 and LL-37, without any enzyme incubation, displayed a similar 
effect as pure peptide. DPK-060 loaded cubosomes performed slightly poorer than pure DPK-
060, a phenomenon not expected by the MIC and time-kill assays. However, the difference 
may be attributed to different killing mechanisms or AMP delivery mechanisms. The MIC 
and time-kill assays were performed on planktonic bacteria, compared to the RDA were the 
bacteria were fixated in an agarose gel. Hence, the bacterial killing in RDA is a result of 
peptide and/or particle diffusion. 
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Interestingly, the RDA showed a significantly better effect of LL-37 post-loaded cubosomes 
after exposure to PE or HNE, compared to unformulated LL-37. These observations were in 
line with the proteolysis data, showing that the cubosomes protected LL-37 from proteolytic 
degradation. Moreover, DPK-060 loaded cubosomes did maintain the peptide’s broad 
spectrum activity after incubation with PE (SA, PA and EC) compared to unformulated 
peptide showing activity only against SA and PA. 
 
Figure 16. Bactericidal effect of references and post-loaded cubosomes after incubation with PE or HNE on SA, 
PA and EC monitored as killing around a pre-formed well in the agar gel containing bacteria. Larger diameter 
corresponds to more effective radial diffusion of the AMP, and in turn bacterial killing. Data is presented as 
mean + standard deviation (n=5 for EC, and n=4 for PA and SA). 
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4. Conclusions 
 
As the number of multi drug resistant bacteria constantly increases around the globe, the 
demand for novel antibiotics and efficient treatment strategies is rising. AMPs have recently 
received a great attention in the scientific community, but adequate drug delivery systems for 
these peptides are still needed, in order to reach the clinic.  
In this thesis, we have demonstrated that AMPs could successfully be loaded in cubic and 
hexagonal LC gels, and in LCNPs using two different peptide loading strategies; pre- and 
post-loading. The main findings are summarized in Table 3. It was demonstrated that the 
AMPs strongly influenced the LC structure of the cubic GMO/water system. The net charge 
and degree of hydrophobicity of the AMPs were found to be important factors, affecting the 
curvature of the LC system, but also the loading efficacy of the LCNPs. However, the 
hexagonal GMO/OA/water gel kept its hexagonal structure upon peptide incorporation. The 
hexagonal LCNPs were found to be very efficient in encapsulating the AMPs, but did not 
display any antimicrobial effect, indicating insufficient delivery of peptide to the bacteria.   
Importantly, the cubic pre- and post-loaded LCNPs showed promising antimicrobial activity, 
and sometimes could a synergetic effect be observed, resulting in a slightly better activity than 
the unformulated AMP. This was the case of post-loaded DPK-060, showing encouraging 
bacterial killing against SA and EC strains. Moreover, it was shown that LL-37 post-loaded 
onto cubosomes did protect the peptide from enzymatic degradation and that the presence of 
cubosomes enhanced the bactericidal effect after proteolysis. Steric hindrance from the 
particle stabilizer (P407) may inhibit a sufficient enzyme-peptide interaction, providing 
protection of the peptide. 
Table 3. Summary of the main conclusions of this thesis.  
System Cubosome Cubosome Hexosome 
AMP loading strategy pre post pre 
Lipid composition GMO GMO GMO/OA 
AMP loading efficacy moderate poor/moderate excellent 
Particle uniformity good excellent moderate 
Antimicrobial activity good good poor 
Proteolytic protection * good * 
Antibacterial effect after proteolysis * good * 
*Not yet investigated 
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5. Future perspectives 
 
So far, we have demonstrated that LCNPs could be used as drug delivery vehicles for AMPs. 
However, the reason for the differences in antimicrobial activity between pre-loaded 
cubosomes and hexosomes remains unclear and could be further investigated.  Is it an 
unsufficient release of peptide or a weaker interaction of the hexosomes with the bacterial 
cells? The high encapsulation efficacy for the hexosomes could be favorable giving rise to an 
effective proteolytic protection, which has so far not been investigated.  
In case of pre- and post-loaded cubosomes the mechanism of delivery of peptide is an 
interesting topic to study. Does the cubosome particle fuse together with the bacterial 
membrane and delivers the peptide? Model bacterial membrane interactions studies using 
quartz crystal microbalance with dissipation monitoring (QCM-D), ellipsometry or neutron 
reflectivity could provide hints about these questions. Moreover, fluorescently marked 
peptides and particles could be used together with fluorescent microscopy techniques to study 
the interaction with live bacterial cells. 
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